The history and contemporary challenges of the US Food and Drug Administration
- PMID: 17379043
- DOI: 10.1016/j.clinthera.2007.01.006
The history and contemporary challenges of the US Food and Drug Administration
Abstract
Background: The year 2006 marks the 100th anniversary of the regulatory agency now known as the US Food and Drug Administration (FDA), the first consumer protection agency of the federal government and arguably the most influential regulatory agency in the world. The FDA thus plays an integral role in the use of pharmaceuticals, not only in the United States but worldwide.
Objective: The goal of this review was to present an overview of the FDA and place its current role in the perspectives of history and contemporary needs.
Methods: Relevant materials for this review were identified through a search of the English-language literature indexed on MEDLINE (through 2006) using the main search terms United States Food and Drug Administration, FDA, history of the FDA, drug approvals, drug legislation, and FDA legislation. Results from the initial searches were then explored further.
Results: The statute that created the bureau which later became the FDA established this agency to prohibit interstate commerce of adulterated foods, drinks, and drugs. The Food, Drug, and Cosmetic Act that replaced it in 1938, and subsequent food and drug laws and amendments, expanded the FDA's responsibilities to cosmetics, medical devices, biological products, and radiation-emitting products. These amendments have also established the FDA as a mainly preventive regulatory agency that relies chiefly on pre-market control. As such, the FDA has played an important role in shaping the modern pharmaceutical industry by making the scientific approach and the clinical trial process the standard for establishing safety and efficacy and by making rigorous scientific analysis the predominant component of the process for pharmaceutical regulation.
Conclusions: As shown in this review, the evolution of the FDA can be described as a series of "crisis-legislation-adaptation" cycles: a public health crisis promoted the passage of congressional legislation, which was then followed by implementation of the law by the FDA. However, the crises the FDA faces currently are likely to be overcome only under strong and permanent leadership willing to redefine the role and procedures of the FDA with an open mind.
Similar articles
-
Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.Food Drug Law J. 2009;64(1):149-69. Food Drug Law J. 2009. PMID: 19998744
-
FDA policy on unapproved drug products: past, present, and future.Ann Pharmacother. 2005 Jul-Aug;39(7-8):1260-4. doi: 10.1345/aph.1E569. Epub 2005 Jun 14. Ann Pharmacother. 2005. PMID: 15956239
-
Unapproved drugs in the United States and the Food and Drug Administration.Adv Ther. 2011 Oct;28(10):842-56. doi: 10.1007/s12325-011-0059-4. Epub 2011 Sep 1. Adv Ther. 2011. PMID: 21894470 Review.
-
The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.Anesth Analg. 2009 Jan;108(1):211-8. doi: 10.1213/ane.0b013e31818c1b27. Anesth Analg. 2009. PMID: 19095852
-
Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.Semin Nucl Med. 2010 Sep;40(5):364-84. doi: 10.1053/j.semnuclmed.2010.05.002. Semin Nucl Med. 2010. PMID: 20674596 Review.
Cited by
-
Americans' Perspectives on Online Media Warning Labels.Behav Sci (Basel). 2022 Feb 23;12(3):59. doi: 10.3390/bs12030059. Behav Sci (Basel). 2022. PMID: 35323378 Free PMC article.
-
Research at the interface of industry, academia and regulatory science.Nat Biotechnol. 2010 May;28(5):432-3. doi: 10.1038/nbt0510-432. Nat Biotechnol. 2010. PMID: 20458309 No abstract available.
-
Clinical trials in dermatology.Int J Womens Dermatol. 2017 Jan 27;3(3):180-183. doi: 10.1016/j.ijwd.2016.12.001. eCollection 2017 Sep. Int J Womens Dermatol. 2017. PMID: 28831432 Free PMC article. Review.
-
c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children - A c4c expert group white paper.Br J Clin Pharmacol. 2022 Dec;88(12):4997-5016. doi: 10.1111/bcp.15119. Epub 2021 Dec 18. Br J Clin Pharmacol. 2022. PMID: 34699077 Free PMC article. Review.
-
What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?Lancet Psychiatry. 2015 Aug;2(8):756-764. doi: 10.1016/S2215-0366(15)00214-X. Lancet Psychiatry. 2015. PMID: 26249306 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials